Market News
Global Biosimulation Market- Recent Developments
New Product Launches
- For instance, in 2022, Certara, a global manufacturer of biosimulation software, announced the release of new versions of its Immunogenicity (IG), Immuno-oncology (IO) and Vaccine Simulators to predict how drugs work and address key questions in the development of novel biologic therapies
- For instance, in 2020, 54gene, a Nigeria-based health tech precision medicine research company, launched its Clinical Research Programme Services (CPS) division. The new business division will provide end-to-end clinical development services, intelligence, logistics, and infrastructure to enable the conduct of clinical trials in Africa, starting out of Nigeria
- In 2022, Dante Labs, a global provider of genomic information and precision medicine, announced new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform
Acquisition and Partnerships
- In 2022, Cadence Design Systems, Inc., an multinational computational software company, entered into a definitive agreement to acquire privately held OpenEye Scientific Software, Inc., a provider of computational molecular modeling and simulation software being widely and increasingly used by pharmaceutical and biotechnology companies for drug discovery
- In 2021, CATO SMS, a global provider of regulatory and clinical research services, announced that it had acquired Nuventra, Inc. to extend its offering into the critical area of clinical pharmacology. Nuventra is one of the industry’s leading clinical pharmacology science and services providers. The acquisition expanded CATO SMS’ portfolio of specialized solutions that support biopharmaceutical companies with drug development, adding a key set of capabilities focused on significantly reducing development risk, costs and timelines.
U.S.: 
U.K. : 
India : 